Shots:

• The P-III IMbrave150 study involves assessing Tecentriq (IV- 1200mg) + Avastin (IV- 15mg/kg) vs Sorafenib (400mg- bid) in 501 (194 from China) patients in a ratio (2:1) in patients with unresectable HCC- prior not treated with systemic therapy
• The Chinese patients demonstrated a 56% improvement in OS- 40% reduction in PFS and is well tolerated with a consistent safety profile
• Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity- by inhibiting VEGF related immunosuppression

Click here ­to­ read full press release/ article 

 Ref: Roche | Image: Roche